The fibrinolytic system in man. (Q38160849)

30 August 2017

1 reference

title

The fibrinolytic system in man. (English)

1 reference

30 August 2017

Collen D

1

1 reference

30 August 2017

Lijnen HR

series ordinal

2

1 reference

30 August 2017

publication date

1 January 1986

1 reference

Critical Reviews in Oncology Hematology

30 August 2017

published in

1 reference

30 August 2017

volume

4

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

249-301

1 reference

THE FIBRINOLYTIC ACTIVITY OF HEMOLYTIC STREPTOCOCCI.

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

STREPTOCOCCAL FIBRINOLYSIS: A PROTEOLYTIC REACTION DUE TO A SERUM ENZYME ACTIVATED BY STREPTOCOCCAL FIBRINOLYSIN

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A PROTEOLYTIC ENZYME OF SERUM: CHARACTERIZATION, ACTIVATION, AND REACTION WITH INHIBITORS.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Fibrinolysis in the animal organism

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Fibrinolytic activity of normal urine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A plasminogen activator in spontaneously active human blood

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Purification and partial characterization of plasminogen activator from human uterine tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Relationship between tissue plasminogen activator and the activators in blood and vascular wall

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Purification and characterization of human kidney plasminogen activator dissimilar to urokinase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The demonstration of urokinase antigen in whole blood

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Demonstration of urokinase-related fibrinolytic activity in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Two types of plasminogen activators secreted by MCP-7 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Purification of plasminogen activator from Rous sarcoma virus transformed chick embryo fibroblasts treated with the tumor promoter phorbol 12-myristate 13-acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The complete amino acid sequence of low molecular mass urokinase from human urine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The glycoprotein nature of human plasminogen activators

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A new approach to studies of the fibrinolytic enzyme system in man

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Fibrinolytic activity related to age in survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Low fibrinolytic activity in the walls of veins in patients with thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Impairment of the diurnal fibrinolytic response in man. Effects of aging, type IV hyperlipoproteinemia, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Altered endogenous fibrinolysis and biochemical factors in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Preoperative prediction of postoperative deep vein thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Role of surface in surface-dependent activation of Hageman factor (blood coagulation Factor XII)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

C1-inactivator-resistant fibrinolytic activity in plasma euglobulin fractions: its relation to vascular activator in blood and its role in euglobulin fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Inhibition of activated haceman factor (factor XIIa) by an inhibitor of the plasminogen activation (PA inhibitor)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Inhibitors of kallikrein in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Evidence for a rapid inhibitor to tissue plasminogen activator in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Identification and Some Properties of a New Fast-Reacting Plasmin Inhibitor in Human Plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The primary inhibitor of plasmin in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Plasminogen activator and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Primary Structure of the B-Chain of Human Plasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Plasminogen: Purification from Human Plasma by Affinity Chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Measurement of the binding of antifibrinolytic amino acids to various plasminogens.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Amino terminal amino acid sequences and carbohydrate of the two major forms of rabbit plasminogen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

On the Rolw of the Carbohydrate Side Chains of Human Plasminogen in Its Interaction with α2‐Antiplasmin and Fibrin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Physico-chemical and proenzyme properties of NH2-terminal glutamic acid and NH2-terminal lysine human plasminogen. Influence of 6-aminohexanoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Activation of human plasminogen by an insoluble derivative of urokinase. Structural changes of plasminogen in the course of activation to plasmin and demonstration of a possible intermediate compound

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Kinetic studies of the urokinase-catalysed conversion of NH2-terminal glutamic acid plasminogen to plasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A comparative study of high molecular weight urokinase and low molecular weight urokinase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Positive regulation of activation of plasminogen by urokinase: differences in Km for (glutamic acid)-plasminogen and lysine-plasminogen and effect of certain alpha, omega-amino acids

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Comparative activation kinetics of mammalian plasminogens

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Kinetic studies of the urokinase catalysed conversion of NH2-terminal lysine plasminogen to plasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Rotational diffusion analysis of the conformational alterations produced in plasminogen by certain antifibrinolytic amino acids

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Studies on the conformational changes of plasminogen induced during activation to plasmin and by 6-aminohexanoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Fibrinogenolysis and Fibrinolysis with Tissue Plasminogen Activator, Urokinase, Streptokinase-Activated Human Globulin, and Plasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Influence of cyanogen-bromide-digested fibrinogen on the kinetics of plasminogen activation by urokinase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Enhancement of the streptokinase-catalyzed activation of human plasminogen by human fibrinogen and its plasminolysis products

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Studies on the kinetics of plasminogen activation by tissue plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The purification and properties of human plasminogen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Plasminogen-plasmin system. V. A stoichiometric equilibrium complex of plasminogen and a synthetic inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Studies on the Lysine-Binding Sites of Human Plasminogen. The Effect of Ligand Structure on the Binding of Lysine Analogs to Plasminogen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Localization of individual lysine-binding regions in human plasminogen and investigations on their complex-forming properties

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A New Method of Isolation and Some Properties of the Heavy Chain of Human Plasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

On the specific interaction between the lysine-binding sites in plasmin and complementary sites in α2-antiplasmin and in fibrinogen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Structural Relationship between "Glutamic Acid" and "Lysine" Forms of Human Plasminogen and Their Interaction with the NH2-Terminal Activation Peptide as Studied by Affinity Chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The AH-site of plasminogen and two C-terminal fragments. A weak lysine-binding site preferring ligands not carrying a free carboxylate function

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Molecular mechanism of physiological fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The isolation and characterization of plasminogen activators (urokinase) from human urine.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Structural relationship between human high and low molecular mass urokinase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A specific disulfide bond associated with the activity of human urokinase. Its topological identification and reductive cleavage followed by kinetic changes in enzymatic reaction and affinity labeling.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Increased plasminogen activator (urokinase) in tissue culture after fibrin deposition

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Plasminogen activator from human embryonic kidney cell cultures. Evidence for a proactivator

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The Inhibition of Urokinase by Alpha2-Macroglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Inhibition of urokinase by complex formation with human alpha1-antitrypsin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

1 reference

7 January 2021

An activator system in blood indispensable for formation of plasmin by streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Kinetic mechanism of the activation of human plasminogen by streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Kinetics of the Reactions between Streptokinase, Plasmin and alpha2-Antiplasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Thrombolytic Therapy with Streptokinase Using a Standard Dosage Scheme

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Purification and characterization of human vascular plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Purification and characterization of a melanoma cell plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Purification and identification of two structural variants of porcine tissue plasminogen activator by affinity adsorption on fibrin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Adaptation of plasminogen activator sequences to known protease structures

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Common evolutionary origin of the fibrin-binding structures of fibronectin and tissue-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Isolation of cDNA sequences coding for a part of human tissue plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Enzymatic properties of the one- and two-chain form of tissue plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Isolation of two variants of native one-chain tissue plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Differential proteolysis and evidence for a residue exchange in tissue plasminogen activator suggest possible association between two types of protein microheterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Identification of plasminogen activator releasing activity in the neurohypophysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Generation of fibrinolytic activity by infusion of activated protein C into dogs

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Influence of protein C activation on blood coagulation and fibrinolysis in squirrel monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Inhibition of plasminogen activator release from transformed chicken fibroblasts by a protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Detection and partial characterization of a chymostatin-sensitive endopeptidase in transformed fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Shedding from the cell surface of normal and cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Regulation of protein secretion in Chinese hamster ovary cells by cell cycle position and cell density. Plasminogen activator, procollagen fibronectin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Inhibition of tissue-type plasminogen activator by conditioned medium from cultured human and porcine vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Detection and partial characterization of an inhibitor of plasminogen activator in human platelets

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A sensitive assay for tissue plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Plasminogen activation by tissue activator is accelerated in the presence of fibrin(ogen) cyanogen bromide fragment FCB-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Stimulation of tissue plasminogen activator by denatured proteins and fibrin clots: a possible additional role for plasminogen activator?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A critical role of lysine residues in the stimulation of tissue plasminogen activator by denatured proteins and fibrin clots

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Studies of the plasmin system. II. Inhibition of plasmin by serum or plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Studies of the plasmin system. III. Physical properties of the two plasmin inhibitors in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Natural inhibitors of fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Molecular forms of plasmin and protease inhibitors in human fibrinolytic post-mortem plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Human serum plasminogen antiactivator: its distinction from antiplasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Immunochemical distinction between antiplasmin and alpha-antitrypsin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Further evidence for the presence of two plasma inhibitors of fibrinolysis distinct from α2-macroglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The primary fibrinolysis inhibitor and trauma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Immunochemical distinction between the inhibitors of plasminogen activation and antiplasmin in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Serum Inhibitors of Fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Inter-α-antiplasmin: Its distinction from antiactivator

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A low molecular weight antiplasmin of human blood platelets

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Isolation and Properties of a Low Molecular Weight Antiplasmin of Human Blood Platelets and Serum

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Platelet alpha 2-antiplasmin is located in the platelet alpha-granules

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Partial purification and characterization of a new fast-acting plasmin inhibitor from human platelets. Evidence for non-identity with the known plasma proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Purification and reaction mechanism of the primary inhibitor of plasmin from human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Affinity-chromatographic purification of human alpha 2-antiplasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Purification and partial primary structure of cyanogen bromide fragments from human alpha 2-antiplasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Circular dichroism studies on α2-antiplasmin and its interactions with plasmin and plasminogen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Inhibition of plasmin by normal and antiplasmin-depleted human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Assay of α2-plasmin inhibitor activity by means of a plasmin specific tripeptide substrate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Studies on plasma antiplasmin activity using a new plasmin specific chromogenic tripeptide substrate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Properties of three different molecular forms of the alpha 2 plasmin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Demonstration of two forms of alpha 2-antiplasmin in plasma by modified crossed immunoelectrophoresis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Studies on a form of alpha 2-antiplasmin in plasma which does not interact with the lysine-binding sites in plasminogen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Kinetic properties of the primary inhibitor of plasmin from human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

On the Kinetics of the Reaction between Human Antiplasmin and Plasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

On the Kinetics of the Reaction between Human Antiplasmin and a Low-Molecular-Weight Form of Plasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

On the structure of the stable complex between plasmin and α2 -antiplasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Emergence in plasma during activation of the coagulation or fibrinolytic systems of neoantigens, associated with the complexes of thrombin or plasmin with their inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A tanned red cell hemagglutination inhibition immunoassay (TRCHII) for the quantitative estimation of thrombin-antithrombin III and plasmin-alpha1-antiplasmin complexes in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A latex agglutination test for rapid quantitative estimation of the plasmin–antiplasmin complex in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Binding of urokinase to plasma proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Inhibitory spectrum of alpha 2-plasmin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The interaction in human plasma of antiplasmin, the fast-reacting plasmin inhibitor, with plasmin, thrombin, trypsin and chymotrypsin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Comparison of the reactions of neutral granulocyte proteases with the major plasma protease inhibitors and with antiplasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

On the reaction of plasmin or plasmin-streptokinase complex with aprotinin or α2-antiplasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Inhibition of Proteases in Coagulation, Kinin-Forming and Complement Systems by α2-Plasmin Inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Identification of the human plasma protein which inhibits fibrinolysis associated with malignant cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Studies on human plasma alpha 2-macroglobulin-enzyme interactions. Evidence for proteolytic modification of the subunit chain structure

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The interaction of alpha2-macroglobulin with proteinases. Binding and inhibition of mammalian collagenases and other metal proteinases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The electrophoretically ‘slow’ and ‘fast’ forms of the α2-macroglobulin molecule

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Physical and chemical properties of human plasma β2-macroglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A thiol-ester in α2-macroglobulin cleaved during proteinase complex formation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Primary structure of the 'bait' region for proteinases in alpha 2-macroglobulin. Nature of the complex

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Sequence location of the reactive thiol ester in human alpha 2-macroglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Relation of internal thioesters to conformational change and receptor-recognition site in α2-macroglobulin complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Proteolysis at a lysine residue abolishes the recetor-recognition site of α2-Macroglobulin complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A Screening Test forα1-Antitrypsin Deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

2 -Macroglobulin, 1 -antitrypsin, and antithrombin III in plasma and serum during fibrinolytic therapy with urokinase.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Inhibition of plasminogen binding to fibrin by α2-plasmin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Influence of alpha 2-plasmin inhibitor on adsorption of plasminogen to fibrin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Histidine-rich glycoprotein in a normal and a clinical population

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Histidine-rich glycoprotein and alpha 2-plasmin inhibitor in inhibition of plasminogen binding to fibrin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The molecular form of alpha 2-antiplasmin with affinity for plasminogen is selectively bound to fibrin by factor XIII

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Amino acid sequence of the factor XIIIa acceptor site in bovine plasma fibronectin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Turnover of fibrinogen, plasminogen, and prothrombin during exercise in man

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Plasmin-antiplasmin complex formation during defibrase infusion in man

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Metabolism of plasminogen in healthy subjects: effect of tranexamic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Turnover of radiolabelled plasminogen and prothrombin in cirrhosis of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Relationship of fibrinolytic system to postoperative thrombotic phenomena

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Fibrinolytic activity of the vein wall after surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Fibrinolytic response to surgery. Labile and stable patterns and their relevance to post-operative deep venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Plasma fibrinolysis and postoperative deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Fibrinolysis and the prediction of postoperative deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Phenformin and ethyloestrenol in recurrent venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A family with reduced plasminogen activator activity in blood associated with recurrent venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Prediction of postoperative leg-vein thrombosis in gynaecological patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Fibrinolytic activity in plasma and deep vein thrombosis after major abdominal surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Plasminogen Paris I: congenital abnormal plasminogen and its incidence in thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Abnormal plasminogen, a case of recurrent thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A new inherited coagulation disorder caused by an abnormal fibrinogen ('fibrinogen Baltimore').

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Fibrinogen Marburg a new genetic variant of fibrinogen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Fibrinogen Copenhagen; an abnormal fibrinogen with defective polymerization and release of fibrinopeptide A, but normal adsorption of plasminogen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A new type of congenital dysfibrinogenaemia with defective fibrin lysis--Dusard syndrome: possible relation to thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The behavior of alpha2-plasmin inhibitor in fibrinolytic states

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Plasmin inhibitor interactions. The effectiveness of alpha2-plasmin inhibitor in the presence of alpha2-macroglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Interaction of plasmin with alpha 2-macroglobulin and alpha 2-antiplasmin in the presence and absence of tranexamic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

α2-antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

α2-Plasmin inhibitor is among acute phase reactants

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Antiplasmin concentrations after surgery: failure of alpha 2-antiplasmin to rise in patients with venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Changes in Antiplasmin and Plasmin Activities during Extreme Hemodilution and Open Heart Surgery in Dogs

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Decreased alpha 2-antiplasmin levels in patients suffering from obstructive peripheral arterial disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Trends in microvascular research. The microembolism syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Plasminogen concentrations and functional activities and concentrations of plasmin inhibitors in plasma samples from normal subjects and patients with septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Role of α2-plasmin inhibitor in the appearance of fibrinolytic activity during urokinase administration, and an evaluation of the optimal urokinase dosage

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Inhibitors of fibrinolysis in diabetic children, mothers, and their newborn

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The inhibition of tissue plasminogen activator and urokinase-induced fibrinolysis by some natural proteinase inhibitors and by plasma and serum from normal and pregnant subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Homozygous alpha 2-antiplasmin deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Congenital Deficiency of α2-Plasmin Inhibitor Associated with Severe Hemorrhagic Tendency *

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Alpha 2-plasmin inhibitor deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

alpha2-Antiplasmin inhibitor deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Hereditary α2-antiplasmin deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The alpha2-plasmin inhibitor levels in liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Reduced histidine-rich glycoprotein levels in plasma of patients with advanced liver cirrhosis. Possible implications for enhanced fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Effect of hepatectomy on the posttraumatic fibrinolysis inhibition and the primary fibrinolysis inhibitor in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

High-dose, brief intravenous streptokinase early in acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Intravenous short-term infusion of streptokinase in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Treatment of deep-vein thrombosis with intermittent streptokinase and plasminogen infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Effects of the synthetic fibrinolytic agents ortho-thymotic acid and S-1623 on the reaction between human plasmin and antiplasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Influence of dextran 70 on the action of the primary fibrinolysis inhibitor (“α2-plasmin inhibitor”)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

On the interaction between dextran and the primary fibrinolysis inhibitor α2-antiplasmin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Mechanism for the inhibitory effect of dextran on α2-plasmin inhibitor activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Tissue plasminogen activator in human plasma measured by radioimmunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Quantitation of tissue-type plasminogen activator in human endothelial cell cultures by use of an enzyme immunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Determination of tissue plasminogen activator by an enzyme-immunoassay method

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

The fibrin plate method for estimating fibrinolytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Regulation of plasminogen activator secretion in mouse peritoneal macrophages. I. - Role of serum studied by a new spectrophotometric assay for plasminogen activators

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Plasminogen activator release during venous stasis and exercise as determined by a new specific assay

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

A sensitive assay for tissue plasminogen activator activity in plasma, using adsorption on lysine-sepharose

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Clot-selective coronary thrombolysis with tissue-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Coronary thrombolysis with recombinant human tissue-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

Thrombolytic treatment with recombinant tissue-type plasminogen activator in a patient with massive pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2886%2980014-2

7 January 2021

10.1016/S1040-8428(86)80014-2

Identifiers

DOI

1 reference

30 August 2017

1 reference